Minerva Neurosciences Inc
Suletud
3.22 -0.92
Ülevaade
Aktsiahinna muutus
24h
Min
3.21
Max
3.44
Sissetulek | 143M 17M |
|---|---|
Töötajad | 7 |
EBITDA | -11M |
Soovitused | Osta |
|---|---|
12 kuu keskmine prognoos | +147.81% upside |
Järgmine tulemuste avaldamine | 4. nov 2026 |
|---|
Turukapital | -37M 135M |
|---|---|
Eelmine avamishind | 4.14 |
Eelmine sulgemishind | 3.22 |
Minerva Neurosciences Inc Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
Minerva Neurosciences Inc Prognoos
Hinnasiht
By TipRanks
147.81% tõus
12 kuu keskmine prognoos
Keskmine 8.5 USD 147.81%
Kõrge 10 USD
Madal 7 USD
Põhineb 2 Wall Streeti analüütiku instrumendi Minerva Neurosciences Inc 12 kuu hinnasihil - viimase 3 kuu andmed.
Finantsandmed
Müügi- ja halduskulud
Maksueelne kasum
Müük
Intressikulud võla pealt
EBITDA
Ärikasum
$
Ettevõttest Minerva Neurosciences Inc
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.